Oleclumab

6 trials 1 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

5 Completed trials

3 Sponsors

9 Countries

Phase III

Phase II

Phase I/II

Phase III: 1 Phase II: 3 Phase I/II: 2

Indications tested

Triple negative breast cancer 2 Breast cancer recurrent 1 Non-small cell lung cancer stage III 1 Non-small cell lung cancer stage II 1 Non-small cell lung cancer 1 Non-small cell lung cancer stage IIIB 1 Hormone receptor positive breast cancer 1 Non-small cell lung cancer stage IIIA 1

Sponsors using this IMP

AstraZeneca AB 3 Institut Jules Bordet 2 Centre Hospitalier Regional De Marseille 1

All trials

6 total

Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting

2023-508852-21-00 Phase II 7 countries AstraZeneca AB
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati… Ended

2023-503999-24-00 Phase III 6 countries AstraZeneca AB
Neo-adjuvant chemotherapy combined with Stereotactic Body Radiotherapy to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9… Ended

2024-511849-19-00 Phase II 2 countries Institut Jules Bordet
A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies … Ended

2024-511646-40-00 Phase I/II 1 country AstraZeneca AB
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Lo… Ended

2024-511850-34-00 Phase I/II 2 countries Institut Jules Bordet
Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study) Ended

2024-515532-72-00 Phase II 1 country Centre Hospitalier Regional De Marseille

Showing 1–6 of 6 trials

← All drugs A–Z